Ethos Technologies Inc. (LIFE) fair value analysis
Nasdaq · Updated 2026-09-12
Ethos Technologies Inc. operates a digital life insurance platform that enables consumers to shop for and purchase life insurance policies online. The company serves customers throughout the United States.
Valuation status
Awaiting full valuationLIFE does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $35.00
- Sector
- Financial Services
- 12-month range
- $11.13–$35.00
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- A
- Leverage
- Low
- RSI zone
- Neutral
- 52-week position
- The top quarter of its range
What our data shows for LIFE
- Our model validated 1 trailing price-to-earnings windows for LIFE, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $11.13–$35.00.
- The 14-day relative strength index sits at a neutral 62.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for LIFE
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent LIFE news
TickrTrends' derived news-sentiment signal for LIFE is currently mixed, computed from recent coverage.
- aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis (manilatimes.net, 2026-09-01)
- aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD (manilatimes.net, 2026-08-07)
What people are saying
Follow the LIFE conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-12 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is LIFE stock undervalued?
LIFE does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is LIFE's TickrTrends verdict?
LIFE is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is LIFE overbought or oversold?
LIFE's 14-day RSI is in neutral territory - neither overbought nor oversold.